206 related articles for article (PubMed ID: 22011985)
1. Vancomycin dosage in overweight and obese children.
Miller M; Miller JL; Hagemann TM; Harrison D; Chavez-Bueno S; Johnson PN
Am J Health Syst Pharm; 2011 Nov; 68(21):2062-8. PubMed ID: 22011985
[TBL] [Abstract][Full Text] [Related]
2. Vancomycin trough concentrations in overweight or obese pediatric patients.
Heble DE; McPherson C; Nelson MP; Hunstad DA
Pharmacotherapy; 2013 Dec; 33(12):1273-7. PubMed ID: 23798327
[TBL] [Abstract][Full Text] [Related]
3. Vancomycin dosing in obese pediatric patients.
Moffett BS; Kim S; Edwards MS
Clin Pediatr (Phila); 2011 May; 50(5):442-6. PubMed ID: 21282257
[TBL] [Abstract][Full Text] [Related]
4. Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations.
Frymoyer A; Guglielmo BJ; Wilson SD; Scarpace SB; Benet LZ; Hersh AL
Pharmacotherapy; 2011 Sep; 31(9):871-6. PubMed ID: 21923588
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin Dosing Considerations in a Real-World Cohort of Obese and Extremely Obese Patients.
Morrill HJ; Caffrey AR; Noh E; LaPlante KL
Pharmacotherapy; 2015 Sep; 35(9):869-75. PubMed ID: 26343549
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of vancomycin dosing for complicated infections in pediatric patients.
Durham SH; Simmons ML; Mulherin DW; Foland JA
Hosp Pediatr; 2015 May; 5(5):276-81. PubMed ID: 25934812
[TBL] [Abstract][Full Text] [Related]
7. Relationship between vancomycin dosage and serum trough vancomycin concentrations in pediatric patients with cystic fibrosis.
Durham SH; Garza KB; Eiland LS
Am J Health Syst Pharm; 2016 Jul; 73(13):969-74. PubMed ID: 27325878
[TBL] [Abstract][Full Text] [Related]
8. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients.
Eiland LS; English TM; Eiland EH
Ann Pharmacother; 2011 May; 45(5):582-9. PubMed ID: 21521865
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
Adane ED; Herald M; Koura F
Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for Non-Therapeutic Initial Steady-State Vancomycin Trough Concentrations in Children and Adolescents Receiving High Empiric Doses of Intravenous Vancomycin.
Buckel WR; Ghobrial S; Tamma PD; Milstone AM; Zhao Y; Hsu AJ
Paediatr Drugs; 2017 Feb; 19(1):43-51. PubMed ID: 27873214
[TBL] [Abstract][Full Text] [Related]
11. Performance of a vancomycin dosage regimen developed for obese patients.
Reynolds DC; Waite LH; Alexander DP; DeRyke CA
Am J Health Syst Pharm; 2012 Jun; 69(11):944-50. PubMed ID: 22610026
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin dosing in children and young adults: back to the drawing board.
Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
[TBL] [Abstract][Full Text] [Related]
13. Vancomycin dosing and target attainment in children.
Hwang D; Chiu NC; Chang L; Peng CC; Huang DT; Huang FY; Chi H
J Microbiol Immunol Infect; 2017 Aug; 50(4):494-499. PubMed ID: 26462708
[TBL] [Abstract][Full Text] [Related]
14. Performance of a divided-load intravenous vancomycin dosing strategy for obese patients.
Denetclaw TH; Yu MK; Moua M; Dowling TC; Steinke D
Ann Pharmacother; 2015 Aug; 49(8):861-8. PubMed ID: 25986008
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin dosing in healthy-weight, overweight, and obese pediatric patients.
Eiland LS; Sonawane KB
J Pediatr Pharmacol Ther; 2014 Jul; 19(3):182-8. PubMed ID: 25309148
[TBL] [Abstract][Full Text] [Related]
16. Vancomycin population pharmacokinetics in neonates.
de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
[TBL] [Abstract][Full Text] [Related]
17. The effect of age and weight on vancomycin serum trough concentrations in pediatric patients.
Madigan T; Sieve RM; Graner KK; Banerjee R
Pharmacotherapy; 2013 Dec; 33(12):1264-72. PubMed ID: 23864541
[TBL] [Abstract][Full Text] [Related]
18. Intravenous Vancomycin Associated With the Development of Nephrotoxicity in Patients With Class III Obesity.
Choi YC; Saw S; Soliman D; Bingham AL; Pontiggia L; Hunter K; Chuang L; Siemianowski LA; Ereshefsky B; Hollands JM
Ann Pharmacother; 2017 Nov; 51(11):937-944. PubMed ID: 28709394
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of a vancomycin loading dose in children.
Demirjian A; Finkelstein Y; Nava-Ocampo A; Arnold A; Jones S; Monuteaux M; Sandora TJ; Patterson A; Harper MB
Pediatr Infect Dis J; 2013 Nov; 32(11):1217-23. PubMed ID: 23817340
[TBL] [Abstract][Full Text] [Related]
20. Empirical Vancomycin Dosing in Pediatric Patients with Congenital Heart Disease and the Impact of Cardiopulmonary Bypass on Trough Concentrations.
Thomas CA; Picone A; Menon S; Willis BC
Pharmacotherapy; 2017 Nov; 37(11):1341-1346. PubMed ID: 28833385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]